Evidence for 5-HT(1B/1D) and 5-HT(2A) Receptors Mediating Constriction of the Canine Internal Carotid Circulation

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2001 Feb 28

PMID 11226128

Citations 4

Authors

D Centurion

M I Ortiz

A Sanchez-Lopez

P de Vries

P R Saxena

C M Villalon

Affiliations

Soon will be listed here.

Abstract

The present study has investigated the preliminary pharmacological profile of the receptors mediating vasoconstriction to 5-hydroxytryptamine (5-HT) in the internal carotid bed of vagosympathectomised dogs. One minute intracarotid infusions of the agonists 5-HT (0.1 - 10 microg min(-1)), sumatriptan (0.3 - 10 microg min(-1); 5-HT(1B/1D)), 5-methoxytryptamine (1 - 100 microg min(-1); 5-HT(1), 5-HT(2), 5-HT(4), 5-ht(6) and 5-HT(7)) or DOI (0.31 - 10 microg min(-1); 5-HT(2)), but not 5-carboxamidotryptamine (0.01 - 0.3 microg min(-1); 5-HT(1), 5-ht(5A) and 5-HT(7)), 1-(m-chlorophenyl)-biguanide (mCPBG; 1 - 1000 microg min(-1); 5-HT(3)) or cisapride (1 - 1000 microg min(-1); 5-HT(4)), resulted in dose-dependent decreases in internal carotid blood flow, without changing blood pressure or heart rate. The vasoconstrictor responses to 5-HT, which remained unaffected after saline, were resistant to blockade by i.v. administration of the antagonists ritanserin (100 microg kg(-1); 5-HT(2A/2B/2C)) in combination with tropisetron (3000 microg kg(-1); 5-HT(3/4)) or the cyclo-oxygenase inhibitor, indomethacin (5000 microg kg(-1)), but were abolished by the 5-HT(1B/1D) receptor antagonist, GR127935 (30 microg kg(-1)). Interestingly, after administration of GR127935, the subsequent administration of ritanserin unmasked a dose-dependent vasodilator component. GR127935 or saline did not practically modify the vasoconstrictor effects of 5-MeO-T. In animals receiving GR127935, the subsequent administration of ritanserin abolished the vasoconstrictor responses to 5-MeO-T unmasking a dose-dependent vasodilator component. The vasoconstriction induced by sumatriptan was antagonized by GR127935, but not by ritanserin. Furthermore, ritanserin (100 microg kg(-1)) or ketanserin (100 microg kg(-1); 5-HT(2A)), but not GR127935, abolished DOI-induced vasoconstrictor responses. The above results suggest that 5-HT-induced internal carotid vasoconstriction is predominantly mediated by 5-HT(1B/1D) and 5-HT(2A) receptors.

Citing Articles

The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Tsujino T, Isayama H, Nakai Y, Ito Y, Togawa O, Toda N J Gastroenterol. 2012; 48(8):982-8.

PMID: 23090004 DOI: 10.1007/s00535-012-0698-5.

5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?.

Neeb L, Meents J, Reuter U Neurotherapeutics. 2010; 7(2):176-82.

PMID: 20430316 PMC: 5084098. DOI: 10.1016/j.nurt.2010.03.003.

Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Villalon C, Centurion D Naunyn Schmiedebergs Arch Pharmacol. 2007; 376(1-2):45-63.

PMID: 17703282 DOI: 10.1007/s00210-007-0179-1.

The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype.

Centurion D, Sanchez-Lopez A, de Vries P, Saxena P, Villalon C Br J Pharmacol. 2001; 132(5):991-8.

PMID: 11226129 PMC: 1572652. DOI: 10.1038/sj.bjp.0703913.

References

Bouchelet I, Case B, Olivier A, Hamel E . No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol. 2000; 129(3):501-8. PMC: 1571865. DOI: 10.1038/sj.bjp.0703081. View

Feniuk W, Hare J, Humphrey P . An analysis of the mechanism of 5-hydroxytryptamine-induced vasopressor responses in ganglion-blocked anaesthetized dogs. J Pharm Pharmacol. 1981; 33(3):155-60. DOI: 10.1111/j.2042-7158.1981.tb13739.x. View

Villalon C, Sanchez-Lopez A, Centurion D, Saxena P . Unravelling the pharmacological profile of the canine external carotid vasodilator '5-HT1-like' receptors: coexistence of sympatho-inhibitory 5-HT1B and postjunctional 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2001; 363(1):73-80. DOI: 10.1007/s002100000333. View

Villalon C, Centurion D, Sanchez-Lopez A, de Vries P, Saxena P . 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Zhongguo Yao Li Xue Bao. 2001; 20(12):1057-67. View

Centurion D, Sanchez-Lopez A, de Vries P, Saxena P, Villalon C . The GR127935-sensitive 5-HT(1) receptors mediating canine internal carotid vasoconstriction: resemblance to the 5-HT(1B), but not to the 5-HT(1D) or 5-ht(1F), receptor subtype. Br J Pharmacol. 2001; 132(5):991-8. PMC: 1572652. DOI: 10.1038/sj.bjp.0703913. View

Vidrio H, Hong E . Vascular tone and reactivity to serotonin in the internal and external carotid vascular beds of the dog. J Pharmacol Exp Ther. 1976; 197(1):49-56. View

Deshmukh S, Meyer J . Cyclic changes in platelet dynamics and the pathogenesis and prophylaxis of migraine. Headache. 1977; 17(3):101-8. DOI: 10.1111/j.1526-4610.1977.hed1703101.x. View

Fozard J, Mobarok Ali A, Newgrosh G . Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds. Eur J Pharmacol. 1979; 59(3-4):195-210. DOI: 10.1016/0014-2999(79)90282-6. View

Rand M, Majewski H, Story D, Loiacono R, Ziogas J . Modulation of neuroeffector transmission. J Cardiovasc Pharmacol. 1987; 10 Suppl 12:S33-44. View

10.

Rosenblum W, Nelson G . Endothelium-dependent constriction demonstrated in vivo in mouse cerebral arterioles. Circ Res. 1988; 63(4):837-43. DOI: 10.1161/01.res.63.4.837. View

11.

Ferrari M, Odink J, Tapparelli C, van Kempen G, Pennings E, BRUYN G . Serotonin metabolism in migraine. Neurology. 1989; 39(9):1239-42. DOI: 10.1212/wnl.39.9.1239. View

12.

Lincoln T, Cornwell T . Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels. 1991; 28(1-3):129-37. DOI: 10.1159/000158852. View

13.

Villalon C, Den Boer M, Heiligers J, Saxena P . Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br J Pharmacol. 1991; 102(1):107-12. PMC: 1917868. DOI: 10.1111/j.1476-5381.1991.tb12140.x. View

14.

Villalon C, Terron J, Hong E . Role of 5-HT1-like receptors in the increase in external carotid blood flow induced by 5-hydroxytryptamine in the dog. Eur J Pharmacol. 1993; 240(1):9-20. DOI: 10.1016/0014-2999(93)90539-t. View

15.

Hoyer D, Clarke D, Fozard J, Hartig P, Martin G, Mylecharane E . International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev. 1994; 46(2):157-203. View

16.

Martin G . Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther. 1994; 62(3):283-324. DOI: 10.1016/0163-7258(94)90048-5. View

17.

Ullmer C, Schmuck K, Kalkman H, Lubbert H . Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett. 1995; 370(3):215-21. DOI: 10.1016/0014-5793(95)00828-w. View

18.

Villalon C, Juan E, Castillo C, Castillo E, Lopez-Munoz F, Terron J . Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br J Pharmacol. 1995; 116(6):2778-84. PMC: 1909126. DOI: 10.1111/j.1476-5381.1995.tb17241.x. View

19.

Schmuck K, Ullmer C, Kalkman H, Probst A, Lubbert H . Activation of meningeal 5-HT2B receptors: an early step in the generation of migraine headache?. Eur J Neurosci. 1996; 8(5):959-67. DOI: 10.1111/j.1460-9568.1996.tb01583.x. View

20.

Skingle M, Beattie D, Scopes D, Starkey S, Connor H, Feniuk W . GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res. 1996; 73(1-2):157-61. DOI: 10.1016/0166-4328(96)00089-7. View